| Pulmonary arterial hypertension

Adempass vs Tracleer

Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.
Deep comparison between: Adempas vs Tracleer with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsTracleer has a higher rate of injection site reactions vs Adempas based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tracleer but not Adempas, including UnitedHealthcare
Sign up to reveal the full AI analysis
Adempas
Tracleer
At A Glance
Oral
Three times daily
Soluble guanylate cyclase (sGC) stimulator
Oral
Twice daily
Endothelin receptor antagonist
Indications
  • Chronic thromboembolic pulmonary hypertension
  • Pulmonary arterial hypertension
  • Pulmonary arterial hypertension
Dosing
Chronic thromboembolic pulmonary hypertension, Pulmonary arterial hypertension Start at 1 mg three times a day (or 0.5 mg if hypotension risk); increase by 0.5 mg no sooner than every 2 weeks as tolerated, to a maximum of 2.5 mg three times a day.
Pulmonary arterial hypertension Adults and patients >12 years and >40 kg: 62.5 mg orally twice daily for 4 weeks, then 125 mg twice daily; patients >12 years and <=40 kg: 62.5 mg twice daily; pediatric patients <=12 years: weight-based dosing ranging from 16 mg to 64 mg twice daily.
Contraindications
  • Pregnancy
  • Concomitant use of nitrates or nitric oxide donors in any form
  • Concomitant use of PDE-5 inhibitors (sildenafil, tadalafil, or vardenafil) or nonspecific PDE inhibitors (dipyridamole or theophylline)
  • Concomitant use of other soluble guanylate cyclase (sGC) stimulators
  • Pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP)
  • Pregnancy
  • Concomitant use with cyclosporine A
  • Concomitant use with glyburide
  • Hypersensitivity to bosentan or any component of the product
Adverse Reactions
Most common (>=3%) Headache, dyspepsia and gastritis, dizziness, nausea, diarrhea, hypotension, vomiting, anemia, gastroesophageal reflux disease, constipation
Serious Embryo-fetal toxicity, hypotension, bleeding
Most common (>=3%) Respiratory tract infection, headache, edema, chest pain, syncope, flushing, hypotension, sinusitis, arthralgia, abnormal serum aminotransferases, palpitations, anemia
Serious Hepatotoxicity, embryo-fetal toxicity, fluid retention, decreased sperm counts, decreases in hemoglobin and hematocrit
Postmarketing Angioedema, unexplained hepatic cirrhosis, liver failure, hypersensitivity/DRESS/anaphylaxis, thrombocytopenia, rash, jaundice, anemia requiring transfusion, neutropenia, leukopenia, nasal congestion, autoimmune hepatitis
Pharmacology
Riociguat is a soluble guanylate cyclase (sGC) stimulator with a dual mode of action: it sensitizes sGC to endogenous nitric oxide (NO) by stabilizing the NO-sGC binding, and directly stimulates sGC via a separate binding site independently of NO, increasing cGMP generation and leading to vasodilation.
Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB, blocking the vasoconstrictive and proliferative effects of endothelin-1, a neurohormone elevated in plasma and lung tissue of patients with PAH.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Adempas
  • Covered on 5 commercial plans
  • PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
View full coverage details ›
Tracleer
  • Covered on 5 commercial plans
  • PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
View full coverage details ›
UnitedHealthcare
Adempas
  • Covered on 4 commercial plans
  • PA (8/8) · Step Therapy (0/8) · Qty limit (6/8)
View full coverage details ›
Tracleer
  • Covered on 4 commercial plans
  • PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
View full coverage details ›
Humana
Adempas
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
View full coverage details ›
Tracleer
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAdempas Co-pay Assistance Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/fillfill
Janssen CarePath Oral PAH Savings Program: Tracleer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdempasView full Adempas profile
TracleerView full Tracleer profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.